Cerebrum and Cardiac Protection With Allopurinol in Neonates With Critical Congenital Heart Disease Requiring Cardiac Surgery With Cardiopulmonary Bypass

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 236 participants.

Also called NCT04217421

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 236 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT04217421
  • EudraCT 2017-004596-31
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Netherlands (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT04217421. Randomized; quadruple masking; primary purpose treatment. Start 2020-02-14 (actual); primary completion 2026-10-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Cerebrum and Cardiac Protection With Allopurinol in Neonates With Critical Congenital Heart Disease Requiring Cardiac Surgery With Cardiopulmonary Bypass
Acronym
CRUCIAL
Condition
Congenital Heart Disease in Children
Condition
Neuroprotection
Intervention (Drug)
Allopurinol
Intervention (Drug)
Mannitol
Lead sponsor
dr. M.J.N.L. Benders (class: other)
Collaborator
ZonMw: The Netherlands Organisation for Health Research and Development (class: other)
Collaborator
University Medical Center Groningen (class: other)
Collaborator
Erasmus Medical Center (class: other)
Collaborator
University Medical Center Nijmegen (class: other)
Collaborator
ACE Pharmaceuticals BV (class: other)

Record details

Record id
cardio:ct-nct04217421
Content hash
0fee79f290b5753a036da2c045a541eef526d58a63d18bfaf9fe9d0089cd90de